Ardelyx Completes Enrollment Ahead of Schedule in Phase 3 IBSRELA Trial for CIC

Key Points
- Ardelyx has fully enrolled its Phase 3 ACCEL trial evaluating IBSRELA in adults with chronic idiopathic constipation, or CIC.
- The study compares twice-daily treatment with placebo over 26 consecutive weeks.
- The primary endpoint assesses durable efficacy in relieving constipation.
- Topline results are expected in the second half of 2027.
- IBSRELA is approved for adults with irritable bowel syndrome with constipation, or IBS-C, but not for CIC.
Ardelyx (NASDAQ: ARDX) has completed enrollment ahead of schedule in a study intended to support a potential expansion into another constipation-related condition.
The milestone advances trial execution, but it does not provide new efficacy or safety findings.
ACCEL Tests Sustained Relief Over 26 Weeks
ACCEL is a multicenter, randomized, double-blind, placebo-controlled Phase 3 trial assessing the safety and efficacy of twice-daily IBSRELA, or tenapanor, in adults with CIC.
The primary endpoint focuses on durable constipation relief over the treatment period. Completing enrollment means all patients have entered the trial—not that treatment and follow-up are finished. Ardelyx expects topline data in the second half of 2027.
Management cited the enrollment pace as evidence of physician interest in additional treatment options. That interest is distinct from evidence that IBSRELA will demonstrate benefit in CIC.
Existing IBS-C Experience Supports Further Evaluation
Ardelyx recently presented ACCEL’s design and rationale at the American College of Gastroenterology Annual Scientific Meeting.
The rationale included post hoc analyses of two Phase 3 tenapanor studies in adults with IBS-C, alongside the recognized symptom continuum between IBS-C and CIC. Those findings supported conducting a dedicated CIC study; they do not establish efficacy in the new population.
IBSRELA’s current U.S. approval remains limited to adults with IBS-C. Any expansion to CIC would require supporting clinical evidence and regulatory review.
Mechanism Targets Intestinal Sodium Absorption
Tenapanor locally inhibits the sodium/hydrogen exchanger 3, or NHE3, in the intestine. By reducing sodium absorption, it retains water within the intestinal lumen, accelerates transit and softens stool.
Ardelyx is evaluating whether this mechanism can provide sustained, meaningful relief for adults with CIC, including patients who continue to experience symptoms despite available therapies.
Investor Takeaway: A Defined Clinical Catalyst in the Second Half of 2027
For ARDX investors, ACCEL represents a potential indication expansion for an existing commercial product rather than development of an entirely new medicine.
Ahead-of-schedule enrollment is an execution milestone. The more consequential test will be whether the trial demonstrates durable relief versus placebo with acceptable safety and tolerability.
The next major catalyst is the expected second-half 2027 readout. No CIC regulatory submission date, approval timeline or revenue forecast was provided.

















